Alta Sciences

AUGUST 29, 2024

billion USD by 2028. Large molecules are less able to penetrate the blood/brain barrier to deliver therapeutic results and thus most CNS-active drugs are small molecules.” --The Altascientist, Issue 33, pg. billion USD in 2023 to $166.53

Drug Development 52

Drug Development Clinical Trials Small Molecule Drugs 52

The Pharma Data

JANUARY 19, 2021

It hopes to raise about $160 million in aggregate principal amount of 7.375% senior notes due 2025 and $270 million in aggregate principal amount of 7.250% senior notes due 2028. Its lead candidate is CLN-081, an oral small molecule designed to be a next-generation, irreversible EGFR inhibitor.

Small Molecule 52

Small Molecule Trials Laboratories Immune Response 52

The Pharma Data

NOVEMBER 8, 2020

It is estimated that there will potentially be 13 million moderate-to-severe acne patients treated with oral antibiotics in the urban Chinese population by 2028, which represents a significant opportunity to launch an innovative product whose clinical development is largely de-risked.

Licensing 52

Licensing Licensing Marketing Production 52

The Pharma Data

SEPTEMBER 15, 2020

27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. Phase 1 data and development plans for danuglipron (PF-06882961), which has the potential to be the first-ever small molecule oral GLP-1RA for treating obesity and type 2 diabetes.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52